journal
Journals Journal of Market Access & Hea...

Journal of Market Access & Health Policy

https://read.qxmd.com/read/38544973/comparative-clinical-effectiveness-and-cost-effectiveness-of-the-cochlear-osia-system-and-baha-attract-system-in-patients-with-conductive-or-mixed-hearing-loss-or-single-sided-deafness
#1
JOURNAL ARTICLE
Matthias Brunner, Manjula Schou, Robert J Briggs, Dell Kingsford Smith
The aim of this study was to evaluate the comparative clinical effectiveness and cost-utility of the active transcutaneous Osia® System versus the passive transcutaneous Baha® Attract System for patients with conductive or mixed hearing loss or single-sided deafness in an Australian healthcare setting. In the absence of direct comparative evidence, an indirect treatment comparison (ITC) of the clinical effectiveness and utility gains was needed. The ITC was informed by three studies identified through a systematic literature review...
March 2024: Journal of Market Access & Health Policy
https://read.qxmd.com/read/38544972/an-inclusive-civil-society-dialogue-for-successful-implementation-of-the-eu-hta-regulation-call-to-action-to-ensure-appropriate-involvement-of-stakeholders-and-collaborators
#2
JOURNAL ARTICLE
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
OBJECTIVES: Stakeholder involvement has long been considered a success factor for a joint European health technology assessment (HTA) process, and its relevance is now anchored in the EU HTA Regulation's (EU HTAR) legislative wording. Therefore, we aimed to explore the roles, challenges, and most important activities to increase the level of involvement per stakeholder group. METHODS: At the 2022 Fall Convention of the European Access Academy (EAA), working groups addressed the involvement of patients, clinicians, regulators, health technology developers (HTD), and national HTA bodies and payers within the EU HTA process...
March 2024: Journal of Market Access & Health Policy
https://read.qxmd.com/read/38445246/welcome-to-the-journal-of-market-access-and-health-policy-under-mdpi-wings
#3
EDITORIAL
Mondher Toumi
No abstract text is available yet for this article.
March 2024: Journal of Market Access & Health Policy
https://read.qxmd.com/read/38445245/publisher-s-note-a-new-chapter-for-the-journal-of-market-access-and-health-policy-jmahp-continued-publication-by-mdpi
#4
EDITORIAL
Clàudia Aunós
No abstract text is available yet for this article.
March 2024: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37954532/inappropriate-dosing-of-direct-oral-anticoagulants-findings-from-a-clinical-vignette-study-and-physician-survey
#5
JOURNAL ARTICLE
Ahmet Fuat, Emmanuel Ako, David Hargroves, Douglas Holden, Amrit Caleyachetty, Matthew Carter, James Harris, Carol Roberts, Nnanyelu Nzeakor, Burcu Vardar, Helen Williams
OBJECTIVE: Direct oral anticoagulants (DOACs) are first-line therapy for stroke prevention for 1.4 million atrial fibrillation (AF) patients in the UK. However, the rates of DOAC dosing below evidence-based recommendations are estimated between 9% and 22%. This study explores specific patient and physician factors associated with prescribing inappropriate DOAC underdoses. METHODS: DOAC-prescribing physicians within the UK completed both a clinical vignette survey, which contained 12 hypothetical patient profiles designed to replicate DOAC prescribing scenarios, and a physician survey to capture sociodemographic, clinical experience, and prescriber-related beliefs and motivations related to DOAC prescribing...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37937314/discounting-health-gain-a-different-view
#6
JOURNAL ARTICLE
Baudouin Standaert, Olivier Ethgen
At least since the Age of Enlightenment, good health has been a tenet for society. Healthy societies could learn better, work harder, improve their wealth, and live longer. Today societies focus on life expectancy, as we value long and healthy lives. As illustrated by the provision of COVID-19 vaccines first for the elderly, societies value life-saving actions. Paradoxically, health economic assessments conventionally devalue long-lasting health through the practice of discounting health benefits along with costs...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37808119/ivabradine-in-patients-with-heart-failure-a-systematic-literature-review
#7
JOURNAL ARTICLE
Zeba M Khan, Jean Baptiste Briere, Elzbieta Olewinska, Fatma Khrouf, Mateusz Nikodem
Background: Heart failure is a chronic disease linked with significant morbidity and mortality, and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic literature review aimed to assess the efficacy, safety, and patient-reported outcomes (PROs) of ivabradine in patients with heart failure (HF) with reduced ejection fraction (HFrEF) in randomized controlled trials (RCTs) and observational studies. Methods: We searched electronic databases from their inception to July 2021 to include studies that reported on efficacy, safety, or PROs of ivabradine in patients with HFrEF...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37692554/patient-perceptions-of-copay-card-utilization-and-policies
#8
JOURNAL ARTICLE
Dimika Cavalier, Bridget Doherty, Gabrielle Geonnotti, Aarti Patel, Wesley Peters, Steven Zona, Lisa Shea
BACKGROUND: Copay cards are intended to mitigate patient out-of-pocket (OOP) expenses. This qualitative, exploratory focus group study aimed to capture patient perceptions of copay cards and copay adjustment programs (CAPs; insurers' accumulator and maximizer policies), which redirect the copay card utilization benefits intended for patients' OOP expenses. METHODS: Patients with chronic conditions were recruited through Janssen's Patient Engagement Research Council program...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37675057/budget-and-health-impact-of-switching-eligible-patients-with-atrial-fibrillation-to-lower-dose-dabigatran
#9
JOURNAL ARTICLE
Tanja Fens, Lisa de Jong, Bregt Kappelhoff, Cornelis Boersma, Maarten J Postma
Objectives: To assess the comparative budget and health impact of lower-dose dabigatran versus reduced doses of apixaban and rivaroxaban in atrial fibrillation (AF) patients eligible for a lower-/reduced-dose due to individual patient characteristics in the Netherlands. Methods: A budget impact model was developed in accordance with ISPOR guidelines. A 3-year-time horizon was considered, and analyses were conducted from a Dutch healthcare payer's perspective. The model applies published data to local AF-epidemiology, allowing calculations to estimate clinical events (strokes and haemorrhages) and costs...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37614557/pharmaceutical-pricing-and-reimbursement-policies-in-algeria-morocco-and-tunisia-comparative-analysis
#10
REVIEW
Hajer Dahmani, Ines Fradi, Leila Achour, Mondher Toumi
OBJECTIVES: In this paper, we outline and compare pharmaceutical pricing and reimbursement policies for in-patent prescription medicines in three Maghreb countries, Algeria, Morocco, and Tunisia, and explore possible improvements in their pricing and reimbursement systems. METHODS: The evidence informing this study comes from both an extensive literature review and a primary data collection from experts in the three studied countries. KEY FINDINGS: Twenty-six local experts where interviewed Intervieweesincluded ministry officials, representatives of national regulatory authorities, health insurance organizations, pharmaceutical procurement departments and agencies, academics, private pharmaceutical-sector actors, and associations...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37614556/systematic-literature-reviews-over-the-years
#11
JOURNAL ARTICLE
Beata Smela, Mondher Toumi, Karolina Świerk, Konrad Gawlik, Emilie Clay, Laurent Boyer
Purpose: Nowadays, systematic literature reviews (SLRs) and meta-analyses are often placed at the top of the study hierarchy of evidence. The main objective of this paper is to evaluate the trends in SLRs of randomized controlled trials (RCTs) throughout the years. Methods: Medline database was searched, using a highly focused search strategy. Each paper was coded according to a specific ICD-10 code; the number of RCTs included in each evaluated SLR was also retrieved. All SLRs analyzing RCTs were included...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37583879/rule-of-prevention-a-potential-framework-to-evaluate-preventive-interventions-for-rare-diseases
#12
JOURNAL ARTICLE
Eddie Gibson, Daniel A Ollendorf, Steven Simoens, David E Bloom, Federico Martinón-Torres, David Salisbury, Johan Louis Severens, Mondher Toumi, Daniel Molnar, Kinga Meszaros, Woo-Yun Sohn, Najida Begum
Background: The benefits of preventive interventions lack comprehensive evaluation in standard health technology assessments (HTA), particularly for rare and transmissible diseases. Objective: To identify possible considerations for future HTA using analogies between the treatment and prevention of rare diseases. Study design: An Expert panel meeting assessed whether one HTA assessment framework can be applied to assess both rare disease treatments and preventive interventions. Experts also evaluated the range of value elements currently included in HTAs and their applicability to rare, transmissible, and/or preventable diseases...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37576087/economic-analysis-of-allogeneic-hematopoietic-stem-cell-transplantation-in-the-bone-marrow-transplant-center-of-tunisia
#13
JOURNAL ARTICLE
Leila Achour, Chema Drira, Mohamed Zied Sboui, Ikram Fazaa, Mohamed Ali Soussi, Senda Hammami, Tarek Ben Othman, Myriam Razgallah Khrouf
Introduction: New procedures and diagnostic tests in hematopoietic stem cell transplantation (HSCT) are associated with a significant increase in costs. The last cost estimate of allogeneic HSCT done in Tunisia was in 1996 and concerned only direct medical costs. Therefore, an updated cost analysis is needed. Objective: Analysis of direct costs during the first-year post-allogeneic HSCT in two groups of patients: Bone Marrow Transplant (Allo-BMT) and Peripheral Blood Stem Cell Transplant (Allo-PBSCT) and identification of factors leading to interindividual variations in costs in order to compare these costs with the budget allocated by the payer (CNAM)...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37533549/rapid-literature-review-definition-and-methodology
#14
REVIEW
Beata Smela, Mondher Toumi, Karolina Świerk, Clement Francois, Małgorzata Biernikiewicz, Emilie Clay, Laurent Boyer
Introduction: A rapid literature review (RLR) is an alternative to systematic literature review (SLR) that can speed up the analysis of newly published data. The objective was to identify and summarize available information regarding different approaches to defining RLR and the methodology applied to the conduct of such reviews. Methods: The Medline and EMBASE databases, as well as the grey literature, were searched using the set of keywords and their combination related to the targeted and rapid review, as well as design, approach, and methodology...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37496728/a-systematic-review-of-the-characteristics-of-data-assessment-tools-to-measure-medical-doctors-work-related-quality-of-life
#15
REVIEW
Miyuki Ezura, Katsuhiko Sawada, Yusuke Takushima, Ataru Igarashi, Lida Teng
PURPOSE: Remarkable progress in healthcare technology has recently been made alongside changes in concepts related to drugs and medical devices. It is speculated that this progress benefits not only patients but also healthcare professionals, such as medical doctors. We performed a systematic review of the characteristics of current data assessment tools to measure medical doctors' work-related quality of life (QOL). METHODS: A literature search was conducted through PubMed and Ichushi-Web in 2020...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37440980/the-impact-of-amortization-of-gene-therapies-funding-on-the-results-and-conclusions-of-cems-and-bims
#16
JOURNAL ARTICLE
Hubert Polek, Justyna Janik, Ewelina Paterak, Monique Dabbous, Michał Pochopień, Mondher Toumi
BACKGROUND: Gene replacement therapy (GRT) is a treatment method used to combat or prevent various diseases. Its high one-off cost constitutes a major obstacle for successful market access. This paper aims to assess and discuss the applicability of amortization in models, such as cost-effectiveness models (CEMs) and budget impact models (BIMs) informing HTA recommendations and reimbursement decisions. METHODS AND FINDINGS: A hypothetical CEA and BIA were considered...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37426574/reply-to-comment-on-increased-reliance-on-physician-assistants-an-access-quality-tradeoff
#17
JOURNAL ARTICLE
Bhavneet Walia, Harshdeep Banga, David Larsen
No abstract text is available yet for this article.
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37405228/budget-impact-analysis-for-avatrombopag-in-the-treatment-of-chronic-primary-immune-thrombocytopenia-in-adult-patients-refractory-to-other-treatments
#18
JOURNAL ARTICLE
Andrea Aiello, Elisa Elena Mariano, Mariangela Prada, Cristina Teruzzi, Nicoletta Martone, Stefano Capri, Giuseppe Carli, Sergio Siragusa
Introduction: Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages. Thrombopoietin receptor agonists (TPO-RAs) are the standard of care second-line therapy for adult patients with chronic immune thrombocytopenia. The first TPO-RAs approved and reimbursed in Italy, eltrombopag and romiplostim, while effective, pose some issues in terms of safety (e.g., hepatotoxicity) or general management (e...
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37405227/transformative-potential-of-artificial-intelligence-in-global-health-policy
#19
EDITORIAL
Ridwan Islam Sifat, Upali Bhattacharya
No abstract text is available yet for this article.
2023: Journal of Market Access & Health Policy
https://read.qxmd.com/read/37325810/access-to-innovative-drugs-and-the-national-reimbursement-drug-list-in-china-changing-dynamics-and-future-trends-in-pricing-and-reimbursement
#20
JOURNAL ARTICLE
Bérengère Macabeo, Liam Wilson, Jianwei Xuan, Ruichen Guo, Petar Atanasov, Linda Zheng, Clement François, Philippe Laramée
BACKGROUND AND OBJECTIVES: Multiple reforms aimed at improving the Chinese population's health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anticipate future trends. METHODS: Targeted reviews of published literature and statistics on the Chinese healthcare system, medical insurance and reimbursement processes were conducted, as well as interviews with five Chinese experts involved in the reimbursement of innovative drugs...
2023: Journal of Market Access & Health Policy
journal
journal
53172
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.